Professor David Leaper, who chaired the expert working group, said: "There is growing concern amongst clinicians that arbitrary withdrawal of silver dressings could lead to increased morbidity and prolonged treatment times. I am delighted that we have been able to bring together a group of experts in wound care from around the world to produce straightforward, clear guidance on how to use silver dressings judiciously to benefit patients."
The consensus guidelines describe which patients with wounds are most likely to benefit from silver dressings and detail how these types of dressings should be used.
Mike Pattrick, Systagenix Global Category Director, said: “Our vision for the future is a world where clinicians are able to prescribe the right therapy on the right patient, each and every time, meaning wounds are healed more efficiently and healthcare costs reduced. Systagenix supports these guidelines for the appropriate use of silver in wound care with the belief that it will benefit both patients and healthcare systems globally.”
The document will be produced in English, French, German, Italian and Spanish and will be available in print and online as a free download from www.woundsinternational.com
This consensus was facilitated by Wounds International and supported by Systagenix and other wound care companies in the form of an unrestricted educational grant.
Established in 2008, following the acquisition of Johnson & Johnson’s professional wound care business, Systagenix supplies over 20 million advanced wound dressings per month into over 100 countries worldwide. Its leading edge product portfolio includes SILVERCEL® NON-ADHERENT, ACTISORB®, INADINE®, PROMOGRAN®, PROMOGRAN PRISMA®, ADAPTIC TOUCH® and TIELLE®. The recently launched WOUNDCHEK™ Protease Status is the first in the Let’s Test® category, which is the entry point to the company’s Let’s Heal® approach to wound care.